Cambrex’s Sustainability Program Reduces Scope 1 and Scope 2 Emissions by 20%

Industry trends

Over the past two decades, the pharmaceutical industry has experienced a notable shift in sustainability practices, with most organizations now integrating Environmental, Social, and Governance (ESG) programs into their core operations. While many initiatives began in the early 2000s as reactions to rising stakeholder expectations and regulatory pressures, ESG programs have evolved into transformational corporate strategies that can yield tangible business benefits.

In this article, we discuss how Cambrex, as a contract development and manufacturing organization (CDMO), has implemented ESG programs aligned to our corporate goals, including top-line growth, cost reduction, and increased employee productivity, while other vendors within the pharmaceutical value chain have lagged in developing actionable, time-based sustainability programs. Simultaneously, our ESG programs are designed to support those of our customers – including the measurement and reduction of Scope 3 emissions within the supply-chain.

Download the full article to learn more.